Contrasting Nemus Bioscience (OTCMKTS:NMUS) and Enliven Therapeutics (NASDAQ:ELVN)

Enliven Therapeutics (NASDAQ:ELVN) and Nemus Bioscience (OTCMKTS:NMUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Insider and Institutional Ownership

95.1% of Enliven Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by insiders. Comparatively, 2.7% of Nemus Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Enliven Therapeutics and Nemus Bioscience”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$71.58 million	($1.90)	-11.83
Nemus Bioscience	N/A	N/A	-$19.19 million	N/A	N/A

Risk and Volatility

Enliven Therapeutics has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Nemus Bioscience has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Enliven Therapeutics and Nemus Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	0	0	4	1	3.20
Nemus Bioscience	0	0	0	0	0.00

Enliven Therapeutics presently has a consensus price target of $38.25, suggesting a potential upside of 70.23%. Given Enliven Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Enliven Therapeutics is more favorable than Nemus Bioscience.

Profitability

This table compares Enliven Therapeutics and Nemus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-29.46%	-27.33%
Nemus Bioscience	N/A	N/A	-924.42%

Summary

Enliven Therapeutics beats Nemus Bioscience on 8 of the 10 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About Nemus Bioscience

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.